Special Issue

Drug Candidates for the Treatment of Breast Cancer

Message from the Guest Editor

Breast cancer has become the most commonly diagnosed cancer globally, and the incidence and number of survivors with this disease continue to increase, with most developed countries reporting 85-90% five-year survival rates. Both the relapse and metastasis of breast cancer remain great challenges. despite advances in chemoprevention, chemotherapy, endocrine therapy, and gene-targeted therapy over the past decades. Innovative therapeutic strategies are still urgently needed. Cancer vaccines and new drugs are attractive options, as they aim to induce a durable response or therapeutic relevance to eradicate breast cancer. We welcome review and original articles that highlight the challenges and opportunities in the development of breast cancer treatment drugs. The topics of interest include, but are not limited to, the following: new positioning of breast cancer treatment drugs; selective optimization and reduction of side effects; the origin and application of synthetic drugs or drug metabolites as new drugs, drug delivery systems, or for nanomaterial applications.

Guest Editor

Prof. Dr. Yi-Chiang Hsu School of Medicine, I-Shou University, Kaohsiung 82445, Taiwan

Deadline for manuscript submissions

closed (31 December 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/114656

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

